FDA Peptide Regulation in 2026: What Providers Need to Know

The regulatory environment for compounded peptides has undergone its most significant transformation in a decade. In recent years, FDA reviews of peptides nominated for compounding, along with the end of the GLP-1 drug shortages, have changed which peptides can be compounded and under what conditions (Willis et al., 2026, Int J Pharm Compd; PMID: 42752426). For providers who prescribe peptide therapies, understanding this evolving landscape is not optional. It is a matter of legal compliance and patient safety.

The foundation of peptide compounding regulation rests on Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act (DQSA) of 2013. 503A pharmacies are traditional compounding pharmacies that prepare medications pursuant to individual patient prescriptions (Quertermous et al., 2018, J Drugs Dermatol; PMID: 30005109). They must be licensed by their state board of pharmacy, follow USP compounding standards, and generally use bulk ingredients that have a USP monograph, are components of FDA approved drugs, or appear on the FDA's 503A bulks list. They are exempt from FDA's current Good Manufacturing Practice (cGMP) requirements and pre market approval, provided they meet specific conditions. 503B outsourcing facilities are registered with the FDA, inspected on a risk based schedule, and must comply with cGMP requirements (McCall et al., 2026, J Am Pharm Assoc (2003); PMID: 42242462). They can compound without individual prescriptions (for "office use" or "anticipatory compounding"), making them the primary source for clinics that stock peptides for in office administration. 503B facilities face more rigorous quality standards, including environmental monitoring, stability testing, and comprehensive batch testing.

The FDA maintains lists of bulk drug substances that can be used in compounding. For peptides, the critical question is whether a specific peptide appears on these lists or qualifies under other exemptions. The FDA has been reviewing peptides nominated for its compounding bulk drug substance lists, including reviews by its Pharmacy Compounding Advisory Committee (Willis et al., 2026, Int J Pharm Compd; PMID: 42752426). Peptides that are components of FDA approved drugs, or that appear on the FDA's bulk drug substance lists, have the clearest compounding pathways. Several peptides popular in functional medicine have been reviewed by the FDA's Pharmacy Compounding Advisory Committee, and their compounding status may change (Willis et al., 2026, Int J Pharm Compd; PMID: 42752426). The FDA has also raised safety concerns about certain peptides and has taken enforcement actions, including warning letters, against some compounders and sellers. Providers prescribing those peptides face potential legal exposure.

The compounding of semaglutide has been the highest profile regulatory issue in the peptide space. During the semaglutide shortage, the FDA's drug shortage provisions allowed compounding pharmacies to produce copies of semaglutide (Belcourt et al., 2026, Ann Pharmacother; PMID: 41689811). Once the FDA declared the shortage resolved, compounding pharmacies could no longer legally sell copies of the commercial product (Belcourt et al., 2026, Ann Pharmacother; PMID: 41689811). The FDA's position is that semaglutide should not be compounded when the commercially manufactured product is available in adequate supply (Belcourt et al., 2026, Ann Pharmacother; PMID: 41689811). Some compounding pharmacies and industry groups challenged FDA shortage decisions in court. Providers should verify the current status of semaglutide compounding in their jurisdiction before prescribing compounded versions, and should be aware that prescribing a compounded version of an available FDA approved drug may create liability risk.

Adding another layer of complexity, individual states have varying regulations on compounding that may be more or less restrictive than federal rules. Some states have enacted their own legislation regarding peptide compounding, telehealth prescribing of peptides, and pharmacy oversight. Providers should be familiar with both federal and state regulations applicable to their practice location and their patients' locations, which is particularly relevant for telehealth practices.

So what should providers do right now? First, audit your peptide sourcing. Confirm that every peptide you prescribe comes from a state licensed 503A pharmacy or an FDA registered 503B outsourcing facility. Verify their registration status, inspection history, and quality certifications. The FDA maintains a searchable database of registered 503B facilities. Second, stay current on the Bulks list. Monitor FDA Federal Register notices and the Peptide Association's regulatory updates for changes to the compounding status of specific peptides. What was compoundable last year may not be today. Third, document medical necessity. For peptides used off label or in clinical contexts where the evidence base is still developing, thorough documentation of medical necessity, informed consent, and clinical rationale is essential for both patient safety and legal protection. Fourth, understand the difference between 'not FDA approved' and 'illegal': off-label prescribing is common in medicine, accounting for about 21% of uses of commonly prescribed drugs in one US analysis (Radley et al., 2006, Arch Intern Med; PMID: 16682577). However, prescribing substances that cannot be lawfully compounded under either 503A or 503B frameworks is a different matter entirely. Fifth, engage with the regulatory process. The FDA accepts public comments on proposed rules and nominations for the Bulks list. Provider organizations, including the Peptide Association, can and should participate in this process to ensure that the regulatory framework reflects clinical reality and patient needs.

The regulatory trajectory is toward greater oversight, not less. This is not inherently a bad thing. Quality standards protect patients, and a clear regulatory framework benefits reputable providers and pharmacies. The challenge is ensuring that regulation is evidence based and does not unnecessarily restrict access to therapeutically valuable peptides that lack commercial sponsors willing to fund the full FDA approval process. The Peptide Association is actively engaged in this process on behalf of our provider and patient communities.